ATE319434T1 - PHARMACEUTICAL COMPOSITION FOR THE CONTROLLED RELEASE OF A BETA-LACTAM ANTIBIOTIC - Google Patents

PHARMACEUTICAL COMPOSITION FOR THE CONTROLLED RELEASE OF A BETA-LACTAM ANTIBIOTIC

Info

Publication number
ATE319434T1
ATE319434T1 AT01274758T AT01274758T ATE319434T1 AT E319434 T1 ATE319434 T1 AT E319434T1 AT 01274758 T AT01274758 T AT 01274758T AT 01274758 T AT01274758 T AT 01274758T AT E319434 T1 ATE319434 T1 AT E319434T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
active ingredient
controlled release
composition
beta
Prior art date
Application number
AT01274758T
Other languages
German (de)
Inventor
Himadri Sen
Rajesh Suresh Kshirsagar
Shailesh Suresh Bhamare
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Application granted granted Critical
Publication of ATE319434T1 publication Critical patent/ATE319434T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

An improved stable pharmaceutical composition for controlled release of an active ingredient comprises a betalactam antibiotic such as cephalexin, cefaclor or their pharmaceutically acceptable hydrates, salts or esters as active ingredient, a calcium salt and a mixture of hydrophilic polymers selected from the group consisting of at least one sodium alginate and one xanthan gum and with or without hydroxypropyl methylcellulose, said composition optionally containing probenecid. The composition may also contain one or more of a water soluble and/or water dispersible diluent, wherein the quantities of the hydrophilic polymers and water soluble and/or water dispersible diluents are such that the therapeutically effective active ingredient is released at a rate suitable for once or twice daily administration of the pharmaceutical composition.
AT01274758T 2001-11-19 2001-11-19 PHARMACEUTICAL COMPOSITION FOR THE CONTROLLED RELEASE OF A BETA-LACTAM ANTIBIOTIC ATE319434T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2001/000204 WO2003043607A1 (en) 2001-11-19 2001-11-19 A pharmaceutical composition for controlled release of a beta-lactam antibiotic

Publications (1)

Publication Number Publication Date
ATE319434T1 true ATE319434T1 (en) 2006-03-15

Family

ID=11076411

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01274758T ATE319434T1 (en) 2001-11-19 2001-11-19 PHARMACEUTICAL COMPOSITION FOR THE CONTROLLED RELEASE OF A BETA-LACTAM ANTIBIOTIC

Country Status (11)

Country Link
US (1) US8192755B2 (en)
EP (1) EP1461017B1 (en)
AT (1) ATE319434T1 (en)
AU (1) AU2002224011B2 (en)
BR (1) BR0117171A (en)
CY (1) CY1105365T1 (en)
DE (1) DE60117712T2 (en)
DK (1) DK1461017T3 (en)
ES (1) ES2259011T3 (en)
PT (1) PT1461017E (en)
WO (1) WO2003043607A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
WO2005039537A1 (en) 2003-10-22 2005-05-06 Lidds Ab Composition comprising biodegradable hydrating ceramics for controlled drug delivery
US7807715B2 (en) * 2006-06-09 2010-10-05 Ucb Pharma Gmbh Pharmaceutical compositions comprising fesoterodine
US9050357B2 (en) * 2010-03-08 2015-06-09 Cp Kelco U.S., Inc. Compositions and methods for producing consumables for patients with dysphagia
RU2470671C1 (en) * 2011-07-06 2012-12-27 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Федерального агентства по здравоохранению и социальному развитию" Method for textile treatment for cardiovascular surgery
CN107661507A (en) * 2017-10-30 2018-02-06 四川飞扬动物药业有限公司 Enteric long-acting composite amoxicillin powder for animals and preparation method thereof
US11554112B2 (en) * 2018-06-07 2023-01-17 Herum Therapeutics International Limited Combinations of β-lactam compounds and probenecid and uses thereof
EP3790535A1 (en) 2019-02-13 2021-03-17 Iterum Therapeutics International Limited Combinations of beta-lactam compounds and probenecid and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6055486B2 (en) * 1976-02-28 1985-12-05 富山化学工業株式会社 Composition for rectal administration of a compound having a β-lactam ring
GB8601204D0 (en) 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
US5419917A (en) 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
IL119627A (en) 1996-11-17 2002-03-10 Yissum Res Dev Co PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
HUP0103632A3 (en) * 1998-09-14 2005-06-28 Ranbaxy Lab Ltd Orally administered controlled drug delivery system providing temporal and spatial control
US6267986B1 (en) 1999-09-24 2001-07-31 Ranbaxy Laboratories Limited Process for the preparation of a controlled drug delivery system containing pseudoephedrine and a long acting antihistamine
AU2003202988A1 (en) 2002-01-14 2003-07-30 The Board Of Trustees Of The University Of Illinois Use of modified pyrimidine compounds to promote stem cell migration and proliferation

Also Published As

Publication number Publication date
AU2002224011B2 (en) 2008-05-01
WO2003043607A1 (en) 2003-05-30
EP1461017B1 (en) 2006-03-08
DE60117712D1 (en) 2006-05-04
AU2002224011A1 (en) 2003-06-10
PT1461017E (en) 2006-07-31
US8192755B2 (en) 2012-06-05
ES2259011T3 (en) 2006-09-16
DE60117712T2 (en) 2006-11-16
BR0117171A (en) 2004-10-26
EP1461017A1 (en) 2004-09-29
DK1461017T3 (en) 2006-06-19
CY1105365T1 (en) 2010-03-03
US20050031685A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
PT923934E (en) FORMULATION OF MODIFIED LIBERTACAO OF CEFACLOR AND CEFALEXIN
AU4882597A (en) Pharmaceutical preparations for the controlled release of beta-lactam antibiotics
FR2811571B1 (en) ORAL PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE AND SUSTAINED ABSORPTION OF AN ACTIVE INGREDIENT
DE60017279D1 (en) Pyrimidinderivate
CA2385890A1 (en) Controlled release compositions comprising nimesulide
WO2002071827A3 (en) Retinoid x receptor modulators
IL314009B2 (en) Parp1 inhibitors and uses thereof
EP1076055A4 (en) 1- (1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
DE69940557D1 (en) A HYDROCOLLOID AND A DELIVERY-RELATED TABLET CONTAINING CELLULOSE ETHER
PL299870A1 (en) 7-beta-[(z)-2-(2-amino-4-thiasolyl)-2-hydroxyiminoacetamide]-3-(1,2,3-triazol-4-yl)-thiomethylothio-3-cephemo-4-carboxylic hydrochloride, crystalline hydrate of 7-beta-[(z)-2-(2-amino-4-thiasolyl)-2-hydroxyiminoacetamide]-3-(1,2,3-triazol-4-yl)-thiomethylothio-3-cephemo-4-carboxylic hydrochloride, method of obtaining these compounds, pharmaceutical preparation and method of fighting against bacteriae
HU229443B1 (en) Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use
GR1003658B (en) Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route
ZA200603538B (en) P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same
DE69716586D1 (en) BUFFERED ORTHOESTER POLYMERS CONTAINING MEDICINAL PRODUCTS
WO2004058721A3 (en) Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity
AP1564A (en) Piperazinyl sulfonic acid derivatives, their pharmaceutical compositions and methods of use.
ATE319434T1 (en) PHARMACEUTICAL COMPOSITION FOR THE CONTROLLED RELEASE OF A BETA-LACTAM ANTIBIOTIC
JP2000159790A5 (en)
WO1998020836A3 (en) Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
CA2502731A1 (en) Sustained release composition for oral administration of drugs
JP2002524410A5 (en)
WO2005051350A3 (en) Water dispersible tablet
AU2001284660A1 (en) Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
AU2003290015A1 (en) Mastitis treatment
WO2005013935A3 (en) Composition for releasing a weak base for an extended period of time

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1461017

Country of ref document: EP

REN Ceased due to non-payment of the annual fee